<!-- Auto-generated from OpenAlex cache. Do not edit by hand. -->
Updated: 157 works; citations 775; h-index 14.

## Publications (recent first)

- 2025: **Semiconducting artificial dendritic cells with biocatalytic and radiosensitive iron centers to eradicate radioresistant squamous cell carcinoma**. DOI: 10.1016/j.celbio.2025.100277
- 2025: **Childhood-onset depression and newly diagnosed chronic diseases after age 65: a large longitudinal cohort study**. DOI: 10.1186/s12888-025-07494-9
- 2025: **Prognostic value of systemic inflammation-modified Patient-Generated Subjective Global Assessment in advanced cancers: A large-scale retrospective cohort study**. DOI: 10.1007/s00520-025-10010-0
- 2025: **Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis**. DOI: 10.2147/jir.s546584
- 2025: **Correction: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)**. DOI: 10.1007/s00262-025-04162-5
- 2025: **Randomized, double‐blind phase <scp>III</scp> trial of a dexamethasone‐free regimen for managing highly emetogenic chemotherapy‐induced nausea and vomiting**. DOI: 10.1002/ijc.70069
- 2025: **Editorial: Opportunities and challenges of head and neck cancer treatment in the era of immune checkpoint inhibitors**. DOI: 10.3389/fimmu.2025.1656915
- 2025: **Systematic inflammation burdens improve the survival prediction value of nutrition assessment in postoperative patients with recurrent or metastatic cancer: A retrospective observational study**. DOI: 10.1002/ncp.11336
- 2025: **Outside Front Cover: Biomimetic Hierarchical Construction of Anti‐Tumor Polyoxopalladates for Cancer Therapy (Angew. Chem. 23/2025)**. DOI: 10.1002/ange.202510019
- 2025: **Outside Front Cover: Biomimetic Hierarchical Construction of Anti‐Tumor Polyoxopalladates for Cancer Therapy (Angew. Chem. Int. Ed. 23/2025)**. DOI: 10.1002/anie.202510019
- 2025: **Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors**. DOI: 10.3389/fonc.2025.1610079
- 2025: **Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors**. DOI: 10.3389/fonc.2025.1539514
- 2025: **Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study**. DOI: 10.1016/j.oraloncology.2024.107161
- 2025: **Multidisciplinary Team Support for Patients With Head and Neck Cancer Receiving Radiotherapy**. DOI: 10.1001/jamanetworkopen.2025.47590
- 2025: **Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)**. DOI: 10.1007/s00262-024-03905-0
- 2025: **Biomimetic Hierarchical Construction of Anti‐Tumor Polyoxopalladates for Cancer Therapy**. DOI: 10.1002/ange.202505564
- 2025: **Neutrophil‐to‐Lymphocyte Ratio as a Predictor for <scp>PD</scp>‐<scp>L1</scp> Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma**. DOI: 10.1002/hed.28101
- 2025: **Biomimetic Hierarchical Construction of Anti‐Tumor Polyoxopalladates for Cancer Therapy**. DOI: 10.1002/anie.202505564
- 2025: **Association of type 2 diabetes, hypertension, and hyperlipidemia with immune-related adverse events in patients undergoing immune checkpoint inhibitors therapy**. DOI: 10.3389/fimmu.2025.1472197
- 2025: **Ultra-high dose rate radiotherapy overcomes radioresistance in head and neck squamous cell carcinoma**. DOI: 10.1038/s41392-025-02184-0
- 2024: **Machine Learning-based Prognostic Model for Brain Metastasis Patients: Insights from Blood Test Analysis**. DOI: 10.7150/jca.103847
- 2024: **Characterizing the impact of sarcopenia on treatment response and survival in previously treated recurrent or metastatic nasopharyngeal carcinoma: Insights from a secondary analysis of the KL-A167 randomized trial.**. DOI: 10.1200/jco.2024.42.16_suppl.6046
- 2024: **Harnessing the Systemic Immunoinflammatory Index as a Potential Predictive Tool for Recurrent or Metastatic Nasopharyngeal Carcinoma Undergoing PD-L1 Inhibitor**. DOI: 10.2147/jir.s474162
- 2024: **Causal effect of gut microbiota on occurrence of herpes zoster and postherpetic neuralgia, and role of Tyzzerella 3**. DOI: 10.1186/s40001-024-02106-w
- 2024: **Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study**. DOI: 10.1016/j.oraloncology.2024.107028
- 2024: **Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta‐analysis**. DOI: 10.1111/cen.15027
- 2024: **Univariable and multivariable Mendelian randomization study identified the key role of gut microbiota in immunotherapeutic toxicity**. DOI: 10.1186/s40001-024-01741-7
- 2024: **Serum tumor markers and outcomes in lung cancer patients with brain metastases: a retrospective longitudinal cohort study**. DOI: 10.21037/tlcr-24-404
- 2024: **Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database**. DOI: 10.3389/fimmu.2024.1439231
- 2024: **Characterizing neuroinflammation and identifying prenatal diagnostic markers for neural tube defects through integrated multi-omics analysis**. DOI: 10.1186/s12967-024-05051-8
